Xencor Inc (NASDAQ:XNCR)

Data as of Oct 17
 -0.23 / -2.21%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Xencor, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. The company uses proprietary XmAb technology platform to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. It focuses on the portion of the antibody that interacts with multiple segments of the immune system, referred to as the Fc domain, which is constant and interchangeable among antibodies. Xencor was founded Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Contact Information

Xencor, Inc.
111 West Lemon Avenue
Monrovia California 91016
P:(626) 305-5900
Investor Relations:



Other institutional46.51%
Individual stakeholders40.67%
Mutual fund holders15.80%

Top Executives

Bassil I. DahiyatPresident, Chief Executive Officer & Director
John J. KuchVice President-Finance
John R. DesjarlaisChief Scientific Officer & Senior VP-Research
Paul A. FosterChief Medical Officer
Lloyd A. RowlandChief Compliance Officer, SVP & General Counsel

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.